Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver

Neoplasia (United States)

Volumn 14, Issue 12, 2012, Pages 1122-1131

  Sun, Xiaowei ^a   Essalmani, Rachid ^a   Day, Robert ^b   Khatib, Abdel M ^c   Seidah, Nabil G ^a   Prat, Annik ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; STAUROSPORINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ADHESION; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; INTESTINE TUMOR; LIVER METASTASIS; MELANOMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA; WESTERN BLOTTING;

EID: 84871592782     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121252     Document Type: Article

References (47)

1. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, and Chretien M (2003). The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 100, 928-933.
2. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al. (2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34, 154-156.
3. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, and Hobbs HH (2005). Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37, 161-165.
4. Cohen JC, Boerwinkle E, Mosley TH Jr, and Hobbs HH (2006). Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354, 1264-1272.
5. Maxwell KN, Fisher EA, and Breslow JL (2005). Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA 102, 2069-2074.
6. Zhang DW, Garuti R, Tang WJ, Cohen JC, and Hobbs HH (2008). Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci USA 105, 13045-13050.
7. Nassoury N, Blasiole DA, Tebon OA, Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A, and Seidah NG (2007). The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8, 718-732.
8. Seidah NG and Prat A (2012). The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11, 367-383.
9. Lan H, Pang L, Smith MM, Levitan D, Ding W, Liu L, Shan L, Shah VV, Laverty M, Arreaza G, et al. (2010). Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells. J Cell Physiol 224, 273-281.
10. Ranheim T, Mattingsdal M, Lindvall JM, Holla OL, Berge KE, Kulseth MA, and Leren TP (2008). Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9. J Cell Physiol 217, 459-467.
11. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, et al. (2008). Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48, 646-654.
12. Mbikay M, Sirois F, Mayne J, Wang GS, Chen A, Dewpura T, Prat A, Seidah NG, Chretien M, and Scott FW (2010). PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 584, 701-706.
13. Benn M, Tybjaerg-Hansen A, Stender S, Frikke-Schmidt R, and Nordestgaard BG (2011). Low-density lipoprotein cholesterol and the risk of cancer: a Mendelian randomization study. J Natl Cancer Inst 103, 508-519.
14. Folsom AR, Peacock JM, and Boerwinkle E (2007). Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence. Cancer Epidemiol Biomarkers Prev 16, 2455-2458.
15. Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, Lazure C, Cianflone K, Seidah NG, and Prat A (2011). Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 31, 785-791.
16. Barbera-Guillem E, Alonso-Varona A, and Vidal-Vanaclocha F (1989). Selective implantation and growth in rats and mice of experimental liver metastasis in acinar zone one. Cancer Res 49, 4003-4010.
17. Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, Asselin MC, Day R, Duclos FJ, Witmer M, et al. (2009). Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem 284, 28856-28864.
18. Sun X, Essalmani R, Seidah NG, and Prat A (2009). The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model. Mol Cancer 8, 73-81.
19. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, and Dove WF (1992). Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668-670.
20. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, and Herz J (1993). Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92, 883-893.
21. Essalmani R, Susan-Resiga D, Chamberland A, Abifadel M, Creemers JW, Boileau C, Seidah NG, and Prat A (2011). In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem 286, 4257-4263.
22. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, and Horton JD (2005). Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 102, 5374-5379.
23. Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, Jammulapati S, Skolnick MH, Hopkins PN, Hunt SC, and Shattuck DM (2004). A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 114, 349-353.
24. Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, Hoth LR, et al. (2007). Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 14, 413-419.
25. Khatib AM, Siegfried G, Chretien M, Metrakos P, and Seidah NG (2002). Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 160, 1921-1935.
26. Barbera-Guillem E, Barcelo JR, Urcelay B, Alonso-Varona AI, and Vidal-Vanaclocha F (1988). Noncorrelation between implantation and growth of tumor cells for their final metastatic efficiency. Invasion Metastasis 8, 266-284.
27. Benjannet S, Saavedra YG, Hamelin J, Asselin MC, Essalmani R, Pasquato A, Lemaire P, Duke G, Miao B, Duclos F, et al. (2010). Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem 285, 40965-40978.
28. Heyninck K and Beyaert R (2001). Crosstalk between NF-κB-activating and apoptosis-inducing proteins of the TNF-receptor complex. Mol Cell Biol Res Commun 4, 259-265.
29. Barkett M and Gilmore TD (1999). Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 18, 6910-6924.
30. Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, Mizuno T, and Tohyama M (1999). Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFκB activation in primary hippocampal neurons. J Biol Chem 274, 8531-8538.
31. Tada K, Okazaki T, Sakon S, Kobarai T, Kurosawa K, Yamaoka S, Hashimoto H, Mak TW, Yagita H, Okumura K, et al. (2001). Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-κB activation and protection from cell death. J Biol Chem 276, 36530-36534.
32. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, and Baldwin AS Jr (1998). NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683.
33. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, and Prat A (2004). Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 24, 1454-1459.
34. Tlsty TD and Coussens LM (2006). Tumor stroma and regulation of cancer development. Annu Rev Pathol 1, 119-150.
35. Chiang LW, Grenier JM, Ettwiller L, Jenkins LP, Ficenec D, Martin J, Jin F, DiStefano PS, and Wood A (2001). An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis. Proc Natl Acad Sci USA 98, 2814-2819.
36. Kysenius K, Muggalla P, Matlik K, Arumae U, and Huttunen HJ (2012). PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cell Mol Life Sci 69, 1903-1916.
37. Eggermont AM, de Wilt JH, and Ten Hagen TL (2003). Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4, 429-437.
38. Alegre JF, Duarte M, Sureda GM, Bretcha BP, Dussan C, Ballester A, Crespo A, and Brugarolas MA (2012). Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas. Cir Esp 90, 114-120.
39. Kritchevsky SB and Kritchevsky D (1992). Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 12, 391-416.
40. Kitahara CM, Berrington de González A, Freedman ND, Huxley R, Mok Y, Jee SH, and Samet JM (2011). Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 29, 1592-1598.
41. Platz EA, Clinton SK, and Giovannucci E (2008). Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 123, 1693-1698.
42. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, and Liauw SL (2010). Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 28, 2653-2659.
43. Murtola TJ, Syvala H, Pennanen P, Blauer M, Solakivi T, Ylikomi T, and Tammela TL (2011). Comparative effects of high and low-dose simvastatin on prostate epithelial cells: the role of LDL. Eur J Pharmacol 673, 96-100.
44. Iso H, Ikeda A, Inoue M, Sato S, and Tsugane S (2009). Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer 125, 2679-2686.
45. Borena W, Strohmaier S, Lukanova A, Bjorge T, Lindkvist B, Hallmans G, Edlinger M, Stocks T, Nagel G, Manjer J, et al. (2012). Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 131, 193-200.
46. Kritchevsky SB, Wilcosky TC, Morris DL, Truong KN, and Tyroler HA (1991). Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res 51, 3198-3203.
47. Broitman SA, Wilkinson J, Cerda S, and Branch SK (1996). Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo. Adv Exp Med Biol 401, 111-130.